https://www.selleckchem.com/pr....oducts/h-1152-dihydr
Furthermore, better performance of TITE-PK is achieved while requiring similar number of patients in the simulated trials. For the scenarios involving one schedule, TITE-PK displays similar performance with alternatives in terms of acceptable dose recommendations. The R and Stan code for the implementation of an illustrative sequential phase I trial example in oncology is publicly available ( https//github.com/gunhanb/TITEPK_sequential ). In phase I oncology trials with sequential multiple schedules, the use of all releva
Me gusta
Comentario
Compartir
